disease-modifying antirheumatic drug

(redirected from Antirheumatic agent)

disease-modifying antirheumatic drug (DMARD)

a classification of antirheumatic agents referring to their ability to modify the course of disease, as opposed to simply treating symptoms such as inflammation and pain. Agents in this group include auranofin, azathioprine, cycloSPORINE, gold salts, hydroxychloroquine, leflunomide, methotrexate, D-penicillamine, and sulfasalazine.

disease-modifying antirheumatic drug

DMARD Rheumatology Any agent–eg, azathioprine, gold, cyclophosphamide, hydroxychloroquin, and MTX–which slows the rate of joint destruction in rheumatoid arthritis

disease-modifying antirheumatic drug

Abbreviation: DMARD
A drug that is used to treat rheumatoid arthritis and acts more slowly but more effectively than nonsteroidal anti-inflammatory drugs. Such drugs include hydroxychloroquine, methotrexate, and tumor necrosis factor inhibitors.
Synonym: slow-acting antirheumatic drug
See also: drug
References in periodicals archive ?
Headquarters: Tokyo, President: Masuji Sugata, "Toyama Chemical") announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey condition required for approval of the antirheumatic agent iguratimod (Eisai brand name: Careram, Toyama Chemical brand name: KOLBET) has been lifted.
Swissmedic, the Swiss agency for therapeutic products, approved tofacitinib 5 and 10 mg twice daily (BID) as monotherapy or in combination with a disease modifying non-biologic antirheumatic agent (DMARD), including methotrexate (MTX), in adult patients with moderate-to-severe active RA who have had an inadequate response or intolerance to MTX.
The ninth member of this group, rituximab (Rituxan), is also used as an antirheumatic agent.
Swissmedic has approved the company's tofacitinib 5 and 10 mg twice-daily (BID) as monotherapy or in combination with a disease modifying non-biologic antirheumatic agent (DMARD), including methotrexate (MTX), in adult patients with moderate-to-severe active RA who have had an inadequate response or intolerance to MTX.
Despite the large number of tuberculosis cases in this stud); the prevalence of antirheumatic agent use was low," and thus independent effects for patients on antirheumatics could not be assessed reliably, the researchers noted.
Among those are antirheumatic agents such as anti-TNF biologics (3) and methotrexate.
Hydroxychloroquine, which may have antispirochetal and anti-inflammatory effects, may be used in the negative PCR patients, and "there may be a role for certain disease-modifying antirheumatic agents in the management of chronic Lyme arthritis, but experience with their use in this setting is limited," they said.
It's unclear whether disease-modifying antirheumatic agents (DMARDs) as first-line therapy in nonrheumatoid rheumatologic diseases are effective because the question has not been studied.
6) Despite the proliferation of antirheumatic agents, methotrexate, a structural analogue of folic acid, remains the gold standard among DMARDs.
Purpose of this contract is to obtain anti-inflammatory and antirheumatic agents (M01) and opioids (N02A) of salicylic acid and its derivatives (N02BA) and aniline (N02BE).
Cytotoxic and antirheumatic agents may treat vascular, ocular, neurological, and joint manifestations.